Novartis AG ADR (NVS)vsWest Pharmaceutical Services Inc (WST)
NVS
Novartis AG ADR
$161.93
+0.38%
HEALTHCARE · Cap: $303.67B
WST
West Pharmaceutical Services Inc
$399.81
+1.87%
HEALTHCARE · Cap: $28.03B
Smart Verdict
WallStSmart Research — data-driven comparison
Novartis AG ADR generates 1624% more annual revenue ($57.36B vs $3.33B). NVS leads profitability with a 17.5% profit margin vs 17.0%. WST appears more attractively valued with a PEG of 3.07. WST earns a higher WallStSmart Score of 56/100 (C).
NVS
Hold48
out of 100
Grade: D+
WST
Buy56
out of 100
Grade: C
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-68.3%
Fair Value
$95.56
Current Price
$161.93
$66.37 premium
Margin of Safety
-43.3%
Fair Value
$171.84
Current Price
$399.81
$227.97 premium
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Every $100 of equity generates 31 in profit
Strong operational efficiency at 34.3%
Generating 5.6B in free cash flow
Safe zone — low bankruptcy risk
Every $100 of equity generates 22 in profit
Conservative balance sheet, low leverage
Strong operational efficiency at 22.5%
Areas to Watch
Premium valuation, high expectations priced in
Trading at 8.2x book value
4.7% revenue growth
Grey zone — moderate risk
Trading at 9.4x book value
Expensive relative to growth rate
Premium valuation, high expectations priced in
Comparative Analysis Report
WallStSmart ResearchBull Case : NVS
The strongest argument for NVS centers on Market Cap, Return on Equity, Operating Margin. Profitability is solid with margins at 17.5% and operating margin at 34.3%.
Bull Case : WST
The strongest argument for WST centers on Altman Z-Score, Return on Equity, Debt/Equity. Profitability is solid with margins at 17.0% and operating margin at 22.5%. Revenue growth of 13.8% demonstrates continued momentum.
Bear Case : NVS
The primary concerns for NVS are P/E Ratio, Price/Book, Revenue Growth.
Bear Case : WST
The primary concerns for WST are Price/Book, PEG Ratio, P/E Ratio. A P/E of 51.0x leaves little room for execution misses.
Key Dynamics to Monitor
NVS profiles as a value stock while WST is a mature play — different risk/reward profiles.
WST carries more volatility with a beta of 1.13 — expect wider price swings.
WST is growing revenue faster at 13.8% — sustainability is the question.
NVS generates stronger free cash flow (5.6B), providing more financial flexibility.
Bottom Line
WST scores higher overall (56/100 vs 48/100), backed by strong 17.0% margins and 13.8% revenue growth. Both earn "Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Novartis AG ADR
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Novartis AG researches, develops, manufactures and markets medical devices worldwide. The company is headquartered in Basel, Switzerland.
Visit Website →West Pharmaceutical Services Inc
HEALTHCARE · MEDICAL INSTRUMENTS & SUPPLIES · USA
West Pharmaceutical Services, Inc. is a designer and manufacturer of injectable pharmaceutical packaging and delivery systems. The company is headquartered in Exton, Pennsylvania.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?